Atara Biotherapeutics, Inc. (ATRA) is a pioneering, California-based biopharmaceutical company specializing in creating treatments for severe diseases with significant unmet medical needs. This includes cancer, autoimmune, and viral diseases. Listed on the NASDAQ under the ticker symbol 'ATRA', Atara Biotherapeutics has established itself as a frontrunner in the highly competitive biotechnology market.
Founded in 2012, Atara Biotherapeutics aims to change the lives of patients through pioneering science, teamwork, and a strong commitment to breakthrough outcomes. The company drives transformational outcomes by leveraging immune engagement, unique platforms, and rigorous scientific and clinical execution. Atara focuses on off-the-shelf, or allogeneic, T-cells, which implies that the T-cells used are not sourced from the patient, making their treatment more accessible and potentially scalable for treatment on a large scale.
In their pursuit of effective treatments, Atara Biotherapeutics has led multiple clinical trials for various debilitating diseases. Among their promising pipelines is 'tabelecleucel,' a viral-specific T-cell immunotherapy, which is currently in Phase 3 development for patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease. If it passes regulatory scrutiny, it would enter the market as the first T-cell immunotherapy of its kind.
The company uses its innovative technology and approach to spark next-level advances in precision immunotherapy. Its invested efforts in developing cutting-edge, T-cell immunotherapies are paving the way to potentially transform the treatment paradigm in cancer and other serious diseases.
Atara Biotherapeutics' mission-driven approach is further demonstrated by the calibre of its extensive team depth and experience. The company boasts its collaboration with world-class, strategic partners that include Memorial Sloan Kettering Cancer Center, Amgen, QIMR Berghofer Medical Research Institute in Australia, and others. This is done to accelerate the development and commercialization of promising, novel therapies.
Moreover, Atara is committed to patient advocacy and works closely with patient advocacy organizations to support and educate patients, caregivers, and healthcare providers. Atara Biotherapeutics, with its strong commitment to finding innovative treatments for unmet medical needs, is definitely a name to watch in the biopharmaceutical sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article provides an AI-generated analysis of Atara Biotherapeutics Inc. (NASDAQ: ATRA), identifying mixed sentiment and a mid-channel oscillation pattern. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The analysis highlights an exceptional short setup with a 153.3:1 risk-reward ratio, targeting a 40.6% downside.
Wall Street Zen has upgraded Atara Biotherapeutics (NASDAQ:ATRA) from "Sell" to "Hold," reflecting an average "Hold" consensus among analysts with an average price target of $9.50. Despite the upgrade, ATRA shares opened down 4.9% at $8.09, with the company reporting a quarterly loss of $0.32 per share and revenue of $0.63 million. Institutional investors hold a significant portion of shares, and CEO Anhco Nguyen recently sold shares to cover tax obligations from vested equity awards.
This article analyzes Atara Biotherapeutics Inc. (NASDAQ: ATRA) for tactical trading, highlighting a strong near and mid-term sentiment despite a weak long-term outlook. It identifies an exceptional 234.0:1 risk-reward setup targeting a 70.2% gain against 0.3% risk. The analysis also provides specific institutional trading strategies, including long, breakout, and short positions, with defined entry zones, targets, and stop losses.
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings that matched analyst expectations for a loss of $0.32 per share, while revenue of $0.63 million surpassed estimates. Despite ongoing negative profitability metrics, the stock rose 3.2% after the announcement. Institutional investors hold a significant portion of the company, and analyst ratings are mixed, with an overall "Hold" rating.
Atara Biotherapeutics (NASDAQ:ATRA) is scheduled to release a quarterly update today. This update is expected to provide clarity on the company's program focus, funding discipline, the quality of current demand, and its ability to translate operating priorities into sustainable performance. The article emphasizes that it offers general information and not financial advice or recommendations.